Processa Pharmaceuticals Files 8-K
Ticker: PCSA · Form: 8-K · Filed: Aug 25, 2025 · CIK: 1533743
| Field | Detail |
|---|---|
| Company | Processa Pharmaceuticals, Inc. (PCSA) |
| Form Type | 8-K |
| Filed Date | Aug 25, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, SEC
TL;DR
Processa Pharma filed an 8-K on 8/25/25, mostly routine stuff.
AI Summary
On August 25, 2025, Processa Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events detailed in the provided text. The company, formerly known as Heatwurx, Inc., is incorporated in Delaware and headquartered in Vero Beach, Florida.
Why It Matters
This 8-K filing indicates Processa Pharmaceuticals, Inc. is providing updates or submitting required financial documentation to the SEC.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for other events and exhibits, not indicating any immediate material adverse changes.
Key Players & Entities
- Processa Pharmaceuticals, Inc. (company) — Registrant
- Heatwurx, Inc. (company) — Former company name
- August 25, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Vero Beach, FL (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Processa Pharmaceuticals, Inc.?
The filing is for 'Other Events' and 'Financial Statements and Exhibits', indicating routine updates or submissions rather than a specific material event.
When was this 8-K report filed?
The report was filed on August 25, 2025.
What was Processa Pharmaceuticals, Inc. formerly known as?
The company was formerly known as Heatwurx, Inc.
In which state is Processa Pharmaceuticals, Inc. incorporated?
Processa Pharmaceuticals, Inc. is incorporated in Delaware.
Where are Processa Pharmaceuticals, Inc.'s principal executive offices located?
The principal executive offices are located at 601 21st Street, Suite 300, Vero Beach, FL 32960.
Filing Stats: 457 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-08-25 17:21:08
Filing Documents
- form8-k.htm (8-K) — 36KB
- 0001641172-25-025421.txt ( ) — 198KB
- pcsa-20250825.xsd (EX-101.SCH) — 3KB
- pcsa-20250825_lab.xml (EX-101.LAB) — 33KB
- pcsa-20250825_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On August 13, 2025, Processa Pharmaceuticals, Inc. (the "Company") filed a proxy statement (the "Proxy Statement") pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, in connection with its 2025 Special Meeting of Stockholders. On August 25, 2025, the Company's board of directors changed the location of the Special Meeting of Stockholders from 601 21 st Street, Suite 300, Vero Beach, FL 32960, as set forth in the Proxy Statement, to 594 East Colorado Blvd. Suite 200 Pasadena, CA 91101. Item 9.01. Financial Statements and Exhibits. Exhibit No. Exhibit Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized, on August 25, 2025. PROCESSA PHARMACEUTICALS, INC. Registrant By: /s/ George Ng George Ng Chief Executive Officer